Miami-based CRO Sitero has acquired eClinical technology from Clario in a move to provide a wider range of services.
Clario’s tech will be integrated with Sitero’s Mentor platform and is designed to improve and advance the management of end-to-end clinical trial life cycles, according to an Aug. 1 press release.
Although financial details of the sale weren’t disclosed, Sitero plans to invest “heavily” in AI in the future to further streamline the clinical trial journey. Key features of the platform include electronic data capture, randomization and trial supply management, clinical trial management systems and electronic consent.
Clario’s CEO Chris Fikry, M.D., said that following a strategic review of its clinical trial solutions business, the sale to Sitero was determined to be “the best path forward.”
Fikry was named chief executive in early July 2022. At the time, company officials were discussing opportunities regarding decentralized and hybrid studies that could be used to increase patient diversity in drug research.